详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Safety and efficacy of zotarolimus-eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE-DIABETES CHINA Study

0| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [a]Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China [b]Cardiovascular Research Institution, Shanghai Jiaotong University School of Medicine, Shanghai, China [c]Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China [d]Peking Union Medical College Hospital, Beijing, China [e]Shanghai Tenth People's Hospital, Shanghai, China [f]Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China [g]Xiamen Cardiovascular Hospital, Xiamen University, Fuzhou, China [h]Wuhan Asia Heart Hospital, Wuhan, China [i]Shanxi Cardiovascular Hospital, Xian, China [j]The Affiliated Hospital of Armed Police Logistics College, Tianjin, China [k]Shanghai Tongji Hospital, Shanghai, China [l]Beijing Chao-Yang Hospital, Beijing, China [m]Northern Jiangsu People's Hospital, Yangzhou, China [n]The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China [o]Beijing Friendship Hospital, Capital Medical University, Beijing, China [p]Tianjin Chest Hospital, Tianjin, China [q]Beijing Anzhen Hospital, Capital Medical University, Beijing, China [r]Peking University Shougang Hospital, Beijing, China [s]Military General Hospital of Beijing PLA, Beijing, China [t]Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China [u]Tong Ren Hospital, Shanghai Jiaotong University of Medicine, Shanghai, China [v]Tianjin First Center Hospital, Tianjin, China [w]Beijing Luhe Hospital, Capital Medical University, Beijing, China [x]Shanghai Pudong New Area Gongli Hospital, Shanghai, China [y]Nanjing First Hospital, Nanjing Medical University, Nanjing, China [z]The Affiiliated Hospital of Xuzhou Medical University, Xuzhou, China [aa]Shanghai Xuhui Central Hospital, Shanghai, China [ab]Aerospace Center Hospital, Beijing, China [ac]Pudong New Area People's Hospital, Shanghai, China [ad]Shidong Hospital of Shanghai Yangpu District, Shanghai, China [ae]Zhejiang Hospital, Hangzhou, China [af]The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China [ag]Shanghai East Hospital Affiliated to Tong Ji University School of Medicine, Shanghai, China

出处：

DOI：

ISSN：

关键词： coronary artery disease diabetes percutaneous coronary intervention revascularization stent thrombosis

摘要：

Background: The RESOLUTE-DIABETES CHINA study was specifically designed to investigate the safety and efficacy of Resolute zotarolimus-eluting stents (ZES; Medtronic, Santa Rosa, CA, USA) in the treatment of diabetic coronary lesions in the Chinese population. Methods: In all, 945 patients with de novo native coronary lesions and type 2 diabetes mellitus were recruited at 32 cardiac centers across the Chinese mainland and were implanted with Resolute ZES. The primary endpoint was target vessel failure (TVF); secondary endpoints were clinical outcomes, namely all-cause death, stroke, bleeding, target lesion revascularization (TLR), target vessel revascularization (TVR), non-TVR, and stent thrombosis (ST). The follow-up period for all endpoints was 12 months after the procedure. Results: In all, 933 patients (98.73%) had clinical follow-up at 12 months. The rate of TVF was 11.60%, whereas the rate of occurrence of secondary endpoints was 5.47%, with four patients (0.43%) having subacute or late ST. There were no significant differences in TVF rates comparing patients with different HbA1c levels or receiving different glucose control treatments (all P > 0.05). Patients with multivessel lesions had higher TVF rates (95% confidence intervals) than those with single-vessel lesions (16.76% [12.10%–22.97%) vs 9.72% [7.79%–12.11%], respectively; P = 0.006). There were no significant differences in TVF rates in patients with or without small vessels, bifurcated lesions, or chronic total occlusions (all P > 0.05). [Correction added on 17 January 2019, after first online publication: in the second sentence of Results section, “TLF” was changed to “TVF”.]. Conclusions: Resolute ZES may perform well in the Chinese diabetic population, especially in those with poor glucose control, complex lesions, and certain unfavorable clinical features. Further studies are needed to determine why ZES perform well in this population. © 2018 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 3 区内分泌学与代谢

最新[2023]版：

大类 | 2 区医学

小类 | 3 区内分泌学与代谢

JCR分区：

出版当年[2017]版：

Q2 ENDOCRINOLOGY & METABOLISM

最新[2023]版：

Q2 ENDOCRINOLOGY & METABOLISM

影响因子： 3 最新[2023版] 3.5 最新五年平均 3.213 出版当年[2017版] 2.764 出版当年五年平均 3.039 出版前一年[2016版] 3.298 出版后一年[2018版]

第一作者：

第一作者机构： [a]Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China [b]Cardiovascular Research Institution, Shanghai Jiaotong University School of Medicine, Shanghai, China

通讯作者：

通讯机构： [a]Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China [b]Cardiovascular Research Institution, Shanghai Jiaotong University School of Medicine, Shanghai, China [*1]Department of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine. No. 197 Rui Jin Er Road, 3rd Floor, 12th Building.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Safety and efficacy of zotarolimus-eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE-DIABETES CHINA Study

文献详情

相关文献